Virax Biolabs Group Ltd. Class A (VRAX) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Virax Biolabs Group Ltd. has launched ImmuneSelect, a new suite of immune profiling solutions aimed at understanding adaptive immunity and post-viral syndromes like Long COVID. The portfolio, introduced at the ESCMID Global 2024 Congress, includes various tools for research use, such as peptide pools and recombinant antibodies, to assess and monitor T-Cell functions. This marks a significant step towards the eventual commercialization of their ViraxImmune T-Cell diagnostic platform.
For further insights into VRAX stock, check out TipRanks’ Stock Analysis page.
